Synergy of type I interferon-A6 and interferon-B naked DNA immunotherapy for cytomegalovirus infection

Immunology and Cell Biology

Volumn 80, Issue 5, 2002, Pages 425-435

  Bartlett, Emmalene J ^a   Cull, Vanessa S ^a   Brekalo, Natalie L ^a   Lenzo, Jason C ^a   James, Cassandra M ^a  

^a MURDOCH UNIVERSITY   (Australia)

Author keywords

Cytomegalovirus; Immunotherapy; Naked DNA; Type I interferon

Indexed keywords

AUTOANTIBODY; GAMMA INTERFERON; INTERFERON; INTERFERON A6; INTERFERON A9; INTERFERON B; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; NAKED DNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; GENE THERAPY; IMMUNIZATION; IMMUNOMODULATION; IMMUNOTHERAPY; INOCULATION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; VIRUS MYOCARDITIS; VIRUS REPLICATION;

ACUTE DISEASE; ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CERCOPITHECUS AETHIOPS; CHRONIC DISEASE; COS CELLS; CYTOKINES; CYTOMEGALOVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; IMMUNIZATION SCHEDULE; IMMUNOTHERAPY, ACTIVE; INJECTIONS, INTRAMUSCULAR; INTERFERON TYPE I; INTERFERON-BETA; MICE; MICE, INBRED BALB C; MUROMEGALOVIRUS; MUSCLE, SKELETAL; MYOCARDITIS; REGENERATION; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; TRANSGENES; VACCINES, DNA; VIRUS REPLICATION;

ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; DNA VIRUSES; MAIZE CHLOROTIC MOTTLE VIRUS; MOUSE CYTOMEGALOVIRUS 1; MURINAE;

EID: 0036379592     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.2002.01103.x     Document Type: Article

References (66)

1. Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-8.
2. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-9.
3. Wang B, Boyer J, Srikantan V et al. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates. DNA Cell Biol. 1993; 12: 799-805.
4. Davis HL, McCluskie MJ, Gerin JL, Purcell RH. DNA vaccine for hepatitis B. Evidence for immunogenicity in chimpanzee and comparison with other vaccines. Proc. Natl Acad. Sci. USA 1996; 93: 7213-8.
5. Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J. Immunol. 1997; 158: 1231-7.
6. Hoffman SL, Doolan DL, Sedegha M et al. Nucleic acid malaria vaccines. Current status and potential. Ann. NY Acad. Sci. 1995; 772: 88-94.
7. Tascon RE, Colston MJ, Ragno S, Stavropoulos E, Gregory D, Lowrie DB. Vaccination against tuberculosis by DNA injection. Nature Med. 1996; 2: 888-92.
8. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nature Med. 1996; 2: 1122-8.
9. Yeow W-S, Lawson CM, Beilharz MW. Antiviral activities of individual murine IFN-α subtypes in vivo. Intramuscular injection of IFN expression constructs reduces cytomegalovirus replication. J. Immunol. 1998; 160: 2932-9.
10. Cull VS, Bartlett E, Lawson CM. Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis. Immunol. 2002; 106: 1-16.
11. Noisakran S, Campbell IL, Carr DJ. Ectopic expression of DNA encoding IFN-α1 in the cornea protects mice from herpes simplex virus type I-induced encephalitis. J. Immunol. 1999; 162: 4184-90.
12. Harle P, Noisakran S, Carr DJ. The application of a plasmid DNA encoding IFN-alpha 1 postinfection enhances cumulative survival of herpes simplex virus type 2 vaginally infected mice. J. Immunol. 2001; 166: 1803-2.
13. Harle P, Cull V, Agbaga M-P et al. Differential effect of murine type I IFN transgenes in antagonising HSV-1 replication. J. Virol. 2002 (in press).
14. Carr DJ, Campbell IL. Transgenic expression of interleukin-6 in the central nervous system confers protection against acute herpes simplex virus type-1 infection. J. Neurovirol. 1999; 5: 449-57.
15. Okada E, Sasaki S, Ishii N et al. Intranasal immunisation of a DNA vaccine with IL-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF) expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J. Immunol. 1997; 159: 3638-47.
16. Raz E, Watanabe A, Baird SM et al. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc. Natl Acad. Sci. USA 1993; 90: 4523-7.
17. Tsuji T, Hamajima K, Fukushima J et al. Enhancement of cell-mediated immunity against HIV-1 induced by coinoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J. Immunol. 1997; 158: 4008-13.
18. Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995; 2: 129-35.
19. Cull VS, Broomfield S, Bartlett EJ, Brekalo NL, James (Lawson) CM. Co-immunisation with type I IFN genes enhances protective immunity against cytomegalovirus infection and myocarditis in gB DNA-vaccinated mice. Gene Therapy 2002; (in press).
20. Fuller GN. Cytomegalovirus and the peripheral nervous system in AIDS. J. Acq. Imm. Def. Syndr. 1992; 5: S33-S36.
21. Fernando S, Booth J, Boriskin Y et al. Association of cytomegalovirus infection with post-transplantation cardiac rejection as studied using polymerase chain reaction. J. Med. Virol. 1994; 42: 396-404.
22. Maisch B, Hufnagel G, Schonian U, Hengstenberg C. The European study of epidemiology and treatment of cardiac inflammatory disease (ESETCID). Eur. Heart J. 1995; 16: 173-5.
23. Wreghitt TG, Hakim M, Gray JJ, Kucia SS, Wallwork J, English TA. Cytomegalovirus infections in heart and lung transplant recipients. J. Clin. Pathol. 1988; 41: 660-7.
24. Herskowitz A, Wu TC, Willoughby SB et al. Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late stage infection with human immunodeficiency virus. J. Am. Coll. Cardiol. 1994; 24: 1025-32.
25. Arbustini E, Grasso M, Diegoli M et al. Histopathological and molecular profile of human cytomegalovirus infections in patients with heart transplants. Am. J. Clin. Pathol. 1992; 98: 205-13.
26. Maisch B, Schonian U, Crombach M et al. Cytomegalovirus associated inflammatory heart muscle disease. Scand. J. Infect. Dis. Supplement 1993; 88: 135-48.
27. Mocarski ES, Abenes GB, Manning WC, Sambucetti LC, Cherrington JM. Molecular genetic analysis of cytomegalovirus gene regulation in growth, persistence and latency. Curr. Top. Microbiol. Immunol. 1990; 154: 47-74.
28. Collins T, Pomeroy C, Jordan MC. Detection of latent cytomegalovirus DNA in diverse organs of mice. J. Infect. Dis. 1993; 168: 725-9.
29. Jordan MC. Interstitial pneumonia and subclinical infection after intranasal inoculation of murine cytomegalovirus. Infect. Immun. 1978; 21: 275-80.
30. Olver SD, Price P, Shellam GR. Cytomegalovirus hepatitis: Characterisation of the inflammatory infiltrate in resistant and susceptible mice. Clin. Exp. Immunol. 1994; 98: 375-81.
31. Lawson CM, O'Donoghue H, Reed WD. The role of T cells in mouse cytomegalovirus induced myocarditis. Immunology 1989; 67: 132-4.
32. Lenzo JC, Fairweather D, Cull VC, Shellam GR, James (Lawson) CM. Characterisation of murine cytomegalovirus myocarditis: Cellular infiltration of the heart and virus persistence. J. Mol. Cell. Cardiol. 2002; 34: 1-12.
33. O'Donoghue H, Lawson CM, Reed WD. Autoantibodies to cardiac myosin in mouse cytomegalovirus myocarditis. Immunol. 1990; 71: 20-8.
34. Fairweather D, Lawson CM, Chapman AJ et al. Wild isolates of murine cytomegalovirus induce myocarditis and antibodies that cross-react with virus and cardiac myosin. Immunol. 1998; 94: 263-70.
35. Lawson CM, O'Donoghue H, Farrell HE, Shellam GR, Reed WD. Murine anti-cytomegalovirus monoclonal antibodies with autoreactivity. Immunol. 1991; 72: 427-33.
36. Lenzo JC, Fairweather D, Shellam GR, Lawson CM. Immunomodulation of murine cytomegalovirus-induced myocarditis in mice treated with lipopolysaccharide and tumour necrosis factor. Cellular Immunol. 2001; 213: 52-61.
37. Matsumori A, Yamada T, Kawai C. Immunmodulating therapy in viral myocarditis. Effects of tumour necrosis factor, interleukin-2 and anti-interleukin-2 receptor antibody in an animal model. Eur. Heart J. 1991; 12: 203-5.
38. Kanda T, McManus JE, Nagai R. et al. Modification of viral myocarditis in mice by interleukin-6. Circ. Res. 1996; 78: 848-56.
39. Nishio R, Matsumori A, Shioi T, Ishida H, Sasayama S. Treatment of experimental viral myocarditis with interleukin-10. Circulation 1999; 100: 1102-8.
40. Kanda T, Tanaka T, Sekiguchi K et al. Effect of interleukin-18 on viral myocarditis: Enhancement of interferon-gamma and natural killer cell activity. J. Mol. Cell. Cardiol. 2000; 32: 2163-71.
41. Gresser I. Biological effects of interferons. Soc. Invest Dermatol. 1990; 95: 66-71.
42. Isaacs A, Lindenmann J. Virus interference I. The interferon. Proc. R. Soc. Lond. B. 1957; 147: 258-67.
43. Fleischmann CM, Fleishmann WR Jr. Effects of hyperthermia on the in vitro antiproliferative activities of HuIFN-α, HuIFN-β, and rHuIFN-γ employed separately and in combination. J. Biol. Reg. Homeostat. Agents 1988; 2: 173-85.
44. Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: Implications for its clinical use. Immunol. Today 1996; 17: 369-72.
45. Biron CA. Interferons α and β as immune regulators - A new look. Immunity 2001; 14: 661-4.
46. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I IFN in vivo. Science 1996; 272: 1947-50.
47. + T cells. J. Exp. Med. 1993; 178: 1655-63.
48. Estes DM, Tuo W, Brown WC, Goin J. Effects of typeI/type II IFN and transforming growth factor-β on B-cell differentiation and proliferation. Definition of costimulation and cytokine requirements for immunoglobulin synthesis and expression. Immunol. 1998; 95: 604-11.
49. Chen C, Okayama H. High efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell Biol. 1987; 7: 2745-52.
50. Busfield SJ, Klinken SP. Erythropoietin-induced stimulation of differentiation and proliferation in J2E cells is not mimicked by chemical induction. Blood 1992; 80: 412-19.
51. Lawson CM, Yeow W-S, Lee CM, Beilharz MW.In vivo expression of an interferon alpha gene by intramuscular injection of naked DNA. J. Interferon Cytokine Res. 1997; 12: 255-61.
52. Bartholomaeus WN, O'Donoghue H, Foti D, Lawson CM, Shellam GR, Reed WD. Multiple autoantibodies following cytomegalovirus infection. Virus distribution and specificity of autoantibodies. Immunol. 1988; 64: 397-405.
53. Lawson CM. Evidence for mimicry by viral antigens in animal models of autoimmune disease including myocarditis. Cell Mol. Life Sci. 2000; 57: 552-60.
54. Kusakabe K, Xin KQ, Katoh H et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J. Immunol. 2000; 164: 3102-11.
55. Rabinovitch A, Suarez-Pinzon WL, Sornesen O, Bleackley RC, Power RF, Rajotte RV. Combined therapy with interleukin-4 and interleukin-10 inhibits autoimmune diabetes recurrence in syngeneic islet-transplanted no-obese diabetic mice. Analysis of cytokine mRNA expression in the graft. Transplantation 1995; 60: 368-74.
56. Tanaka M, Saijo Y, Sato G et al. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma. Cancer Gene Ther. 2000; 7: 1481-90.
57. Tay CH, Welsh RM. Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J. Virol. 1997; 71: 267-75.
58. Reddehase MJ. The immunogenicity of human and murine cytomegaloviruses. Curr. Opin. Immunol. 2000; 12: 390-6.
59. Loenen WA, Bruggeman CA, Wiertz EJ. Immune evasion by human cytomegalovirus: Lessons in immunology and cell biology. Seminars Immunol. 2001; 13: 41-9.
60. Miller DM, Zhang Y, Rahill BM, Waldman WJ, Sedmak DD. Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction. J. Immunol. 1999; 162: 6107-13.
61. Anderson CC, Matzinger P. Danger: The view from the bottom of the cliff. Sem. Immunol. 2000; 12: 231-8.
62. Lawson CM, O'Donoghue HL, Reed WD. Mouse cytomegalovirus infection induces antibodies which cross-react with virus and cardiac myosin. A model for the study of molecular mimicry in the pathogenesis of viral myocarditis. Immunol. 1992; 75: 513-9.
63. + T cells in vivo by IL-15. Immunity 1998; 8: 591-9.
64. Cousens LP, Peterson R, Hsu S et al. Two roads diverged: Interferon alpha/beta- and IL-12-mediated pathways in promoting T cell interferon gamma responses during viral infection. J. Exp. Med. 1999; 189: 1315-28.
65. Shui FS, Ljunggren HS, Sarvetnik N. Innate immunity and autoimmunity: From self-protection to self-destruction. Trends Immunol. 2001; 22: 97-101.
66. Baron S, Tyring SK, Fleischmann WR et al. The interferons. Mechanisms of action and clinical applications. JAMA 1991; 266: 1375-83.